{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:01:24Z","timestamp":1787169684956,"version":"build-2736575974"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Cost, adverse events, and long treatment duration can be significant obstacles in treating hepatitis C virus (HCV)-infected individuals. Shortening the treatment regimen can minimize these barriers, thereby enhancing adherence and increasing medication availability to more patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This is a single-centre, single-arm, open-label, phase 3 clinical trial on treatment na\u00efve, non-cirrhotic, HCV genotype 4 patients. The study aimed to evaluate an 8-week course of Elbasvir (ELB)\/Grazoprevir (GZR) in this population. The primary endpoint was sustained virologic response at 12 weeks after the end of treatment (SVR-12). The secondary endpoints were SVR-4, adverse events, and changes in health- and hepatitis-related quality of life (HRQoL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of the 30 patients who were enrolled, 29 (97%) achieved SVR-12 and SVR-4 (95% CI: 90-100%). No patients experienced serious or life-threatening adverse events (AEs), but mild\/moderate AEs were reported by 16 (53%). The most commonly reported AEs were itching\/skin rash (20%), headache (16.7%), abdominal\/epigastric pain and decreased appetite (13.3% each), and nausea\/vomiting (10%). Marked improvements in HRQoL were reported between the first (baseline) and third (SVR-12) timepoints. HRQoL score improvements involved the physical, mental, and hepatitis-specific indices, and ranged between 6 and 42 points (out of 100, P \u22640.003).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The trial provides empirical evidence that HCV genotype 4-infected patients can achieve viral eradication with an 8-week-regimen of ELB\/GZR. Further, this course of treatment is associated with a minimal adverse event profile and potentially significant improvements in quality of life. (ClinicalTrials.gov number, NCT03578640).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/sjg.sjg_374_21","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T05:52:32Z","timestamp":1644385952000},"page":"225-232","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["The efficacy of Elbasvir\/Grazoprevir fixed-dose combination for 8 weeks in HCV treatment and health-related quality of life (HRQoL) in treatment-na\u00efve, non-cirrhotic, genotype 4-infected patients (ELEGANT-4)"],"prefix":"10.4103","volume":"28","author":[{"given":"Ahmad","family":"AlEid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areej","family":"Al Balkhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"Qutub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahem","family":"Abbarh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abed","family":"AlLehibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Almtawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawwaf","family":"Al Otaibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"AlGhamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"AlGhamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman","family":"Alamr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shameem","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Al Sayari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashaar","family":"Al Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"AlKhathlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-9-20240829","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study","volume":"2","author":"Blach","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R5-9-20240829","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/liv.13673","article-title":"Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure","volume":"38","author":"Asselah","year":"2018","journal-title":"Liver Int"},{"key":"R6-9-20240829","doi-asserted-by":"crossref","first-page":"296","DOI":"10.7326\/0003-4819-132-4-200002150-00008","article-title":"Pathogenesis, natural history, treatment, and prevention of hepatitis C","volume":"132","author":"Liang","year":"2000","journal-title":"Ann Intern Med"},{"key":"R9-9-20240829","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1517\/14656566.2016.1161028","article-title":"Grazoprevir+elbasvir for the treatment of hepatitis C virus infection","volume":"17","author":"Alric","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"R12-9-20240829","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1111\/liv.13727","article-title":"Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis","volume":"38","author":"Asselah","year":"2018","journal-title":"Liver Int"},{"key":"R13-9-20240829","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hep.28877","article-title":"Short-duration treatment with elbasvir\/grazoprevir and sofosbuvir for hepatitis C: A randomized trial","volume":"65","author":"Lawitz","year":"2017","journal-title":"Hepatology"},{"key":"R14-9-20240829","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(14)61793-1","article-title":"Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV\/hepatitis C virus co-infection (C-WORTHY): A randomised, open-label phase 2 trial","volume":"385","author":"Sulkowski","year":"2015","journal-title":"Lancet"},{"key":"R15-9-20240829","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/infdis\/jiz154","article-title":"An open-label, randomized, active-controlled trial of 8 versus 12 weeks of elbasvir\/grazoprevir for treatment-naive patients with chronic hepatitis C genotype 1b infection and mild fibrosis (EGALITE study): Impact of baseline viral loads and NS5A resistance-associated substitutions","volume":"220","author":"Huang","year":"2019","journal-title":"J Infect Dis"},{"key":"R16-9-20240829","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/liv.14313","article-title":"Efficacy and safety of elbasvir\/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study","volume":"40","author":"Asselah","year":"2020","journal-title":"Liver Int"},{"key":"R18-9-20240829","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","author":"Pawlotsky","year":"2018","journal-title":"J Hepatol"},{"key":"R19-9-20240829","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7150\/ijms.3.47","article-title":"The natural history of hepatitis C virus (HCV) infection","volume":"3","author":"Chen","year":"2006","journal-title":"Int J Med Sci"},{"key":"R20-9-20240829","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jhep.2014.07.012","article-title":"Natural history of hepatitis C","volume":"61","author":"Westbrook","year":"2014","journal-title":"J Hepatol"},{"key":"R21-9-20240829","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/jgh.12475","article-title":"Role of IL28B for chronic hepatitis C treatment toward personalized medicine","volume":"29","author":"Matsuura","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"R22-9-20240829","doi-asserted-by":"crossref","first-page":"ofz070","DOI":"10.1093\/ofid\/ofz070","article-title":"Predictors of hepatitis C treatment failure after using direct-acting antivirals in people living with human immunodeficiency virus","volume":"6","author":"Cachay","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"R23-9-20240829","first-page":"103","article-title":"Understanding hepatitis C virus drug resistance: Clinical implications for current and future regimens","volume":"25","author":"Wyles","year":"2017","journal-title":"Top Antivir Med"},{"key":"R24-9-20240829","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jhep.2016.02.042","article-title":"Sofosbuvir\/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial","volume":"65","author":"Younossi","year":"2016","journal-title":"J Hepatol"},{"key":"R25-9-20240829","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S2468-1253(17)30116-4","article-title":"Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4\u20135 chronic kidney disease: Clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial","volume":"2","author":"Bruchfeld","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R27-9-20240829","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.2147\/PPA.S172732","article-title":"Patient-reported outcomes in individuals with hepatitis C virus infection treated with elbasvir\/grazoprevir","volume":"12","author":"Ng","year":"2018","journal-title":"Patient Prefer Adherence"}],"container-title":["Saudi Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_374_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:10:10Z","timestamp":1787166610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_374_21"}},"subtitle":["A single-center, single-arm, open-label, phase 3 trial"],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/sjg.sjg_374_21","relation":{},"ISSN":["1319-3767"],"issn-type":[{"value":"1319-3767","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}